Categories: Health

Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to Board of Directors

BRADENTON, Fla., Aug. 6, 2025 /PRNewswire/ — Continuity Biosciences, a company pioneering next-generation combination product drug delivery, today announced the appointment of two highly distinguished leaders to its Board of Directors: Josephine M. Torrente, Director at Hyman, Phelps & McNamara, P.C., and Dr. Joseph M. DeSimone, serial entrepreneur and professor at Stanford University. These appointments mark a significant step forward in Continuity’s mission to advance transformative drug delivery technologies, supported by world-class regulatory expertise and materials science innovation.

- Advertisement -

Josephine M. Torrente

- Advertisement -
  • Current Role: Director, Hyman, Phelps & McNamara, P.C., the largest dedicated FDA regulatory law firm in the U.S.
  • Experience: Over 30 years advising pharmaceutical and biotechnology companies on FDA regulatory strategy, product development, and lifecycle management
  • Strategic Contribution: Ms. Torrente’s deep regulatory insight will guide Continuity’s clinical development and FDA engagement strategies as the company scales its pipeline

Dr. Joseph M. DeSimone

- Advertisement -
  • Current Role: Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering, Stanford University
  • Honors and Recognition: National Medal of Technology and Innovation recipient; inventor on 200+ patents; author of 350+ scientific publications; One of only 25 people elected into all three US National Academies- Science, Engineering and Medicine
  • Entrepreneurial Leadership: Co-founder of Carbon (developer of CLIP 3D printing); founder of Focal Medical (acquired by Continuity) and PinPrint, a 3D microdispensing platform in which Continuity has made a strategic investment
  • Strategic Contribution: Dr. DeSimone’s expertise in materials science, digital manufacturing, and drug delivery perfectly aligns with Continuity’s platform focus on localized, precision therapeutics

Executive Commentary

- Advertisement -

“We are honored to welcome Josephine and Joe to our Board,” said Bob Whitehead, Co-Founder and Executive Chairman of Continuity Biosciences. “Josephine’s regulatory acumen and clear-eyed judgment are second to none. Joe is not only a visionary in drug delivery but also a trusted partner in our efforts through Focal Medical and PinPrint. Their expertise will be instrumental as we continue to scale our programs and build long-term value.”

- Advertisement -

Torrente and DeSimone join Continuity’s existing Board of Directors, which includes Bob Whitehead and Ramakrishna Venugopalan, PhD, MBA (Continuity’s co-founders), Monica Reed, MD, Mike Fowler, and Allen Weiss.

- Advertisement -
  • Krishna Venugopalan formerly led combination product development at AbbVie, contributing to flagship therapies Skyrizi and the newly launched Vyalev—both high-impact combination products
  • Mike Fowler is CEO of Affordable Housing Partners, Inc., which is a subsidiary of Berkshire Hathaway
  • Allen Weiss served as the President of Worldwide Operations for Walt Disney Parks and Resorts (now known as Disney Parks, Experiences and Products)
  • Monica Reed is CEO of UChicago Medicine AdventHealth, where she oversees the strategic development and growth of the health system’s Great Lakes Region, including four hospitals and more than 50 sites of care

About Continuity Biosciences

- Advertisement -

Founded in 2024, Continuity Biosciences is developing advanced delivery platforms for biologics and complex therapeutics, with a focus on precision targeting and tunable release. Operating in Houston (TX), Raleigh (NC), Bradenton (FL), and Torino (Italy), Continuity’s pipeline spans oncology, metabolic diseases, infectious diseases, and women’s health. Through strategic acquisitions—including Focal Medical—and targeted investments like PinPrint, Continuity is building a differentiated platform to transform the delivery of challenging therapeutics.

- Advertisement -

Logo – https://mma.prnewswire.com/media/2555793/Continuity_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/continuity-biosciences-appoints-josephine-torrente-and-joseph-desimone-phd-to-board-of-directors-302522793.html

- Advertisement -
PRNW Agency

Recent Posts

Creddinv ONE: Unified Wealth Platform Exceeds 100 Crore AUM in 3 Months

Bridging the gap between traditional and alternative investments with a unified, research-driven approach to wealth…

3 hours ago

Innovation in the Spotlight: Microvast at All-Energy Australia 2025

MELBOURNE, Australia, Oct. 30, 2025 /PRNewswire/ -- Microvast Holdings, Inc. (NASDAQ: MVST) ("Microvast", the "Company"…

3 hours ago

Goyaz Secures Series A Investment from Norwest

HYDERABAD, India, Oct. 30, 2025 /PRNewswire/ -- Goyaz, India's fastest-growing occasion-led gold-plated silver jewelry brand, today…

3 hours ago

China Pavilion at Osaka Expo 2025 wins the Gold Award! Unilumin provides a comprehensive multimedia solution

OSAKA, Japan, Oct. 30, 2025 /PRNewswire/ -- On the evening of October 12, 2025, the…

4 hours ago

Parcel Perform Defines ‘GEO’ for E-Commerce with Launch of AI Commerce Visibility

Brands can now track, analyze and optimize their visibility across AI shopping agents like ChatGPT, Perplexity,…

4 hours ago

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025

October 29, 2025 20:00 ET  | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL ROCKVILLE, Md. and SUZHOU,…

7 hours ago